AgomAb Therapeutics NV American Depositary Shares Total Assets
AgomAb Therapeutics NV American Depositary Shares total assets. Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) holds total assets worth $165.63 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does AgomAb Therapeutics NV American Deposita generate cash for how efficiently the company converts equity into cash flow.
Total Assets of AgomAb Therapeutics NV American Depositary Shares (2021–2025)
Total assets of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025. This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's total assets have evolved over time, based on quarterly financial data. See AgomAb Therapeutics NV American Deposita stock price for real-time trading data and today's change.
AgomAb Therapeutics NV American Depositary Shares - Asset Composition Analysis
AgomAb Therapeutics NV American Depositary Shares Total Assets Breakdown (December 2025)
AgomAb Therapeutics NV American Depositary Shares total assets breakdown as of December 2025. AgomAb Therapeutics NV American Depositary Shares's total assets of $165.63 Million consist of 78.9% current assets and 21.1% non-current assets. Explore AGMB current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 56.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $20.11 Million | 13.1% |
| Goodwill | $8.61 Million | 5.6% |
Asset Composition Trend (2021–2025)
This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AgomAb Therapeutics NV American Depositary Shares's current assets represent 78.9% of total assets in 2025, an increase from 64.8% in 2021.
- Cash Position: Cash and equivalents constituted 56.2% of total assets in 2025, down from 63.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, a decrease from 33.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 13.1% of total assets.
AgomAb Therapeutics NV American Depositary Shares Competitors by Total Assets
Key competitors of AgomAb Therapeutics NV American Depositary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
AgomAb Therapeutics NV American Depositary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.99 | 19.05 | 19.05 |
| Quick Ratio | 13.99 | 19.05 | 19.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $123.50 Million | $164.72 Million | $164.72 Million |
AgomAb Therapeutics NV American Depositary Shares - Advanced Valuation Insights
This section examines the relationship between AgomAb Therapeutics NV American Depositary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.21 |
| Latest Market Cap to Assets Ratio | 2.55 |
| Asset Growth Rate (YoY) | -25.5% |
| Total Assets | $153.71 Million |
| Market Capitalization | $391.52 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values AgomAb Therapeutics NV American Depositary Shares's assets at a significant premium (2.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: AgomAb Therapeutics NV American Depositary Shares's assets decreased by 25.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AgomAb Therapeutics NV American Depositary Shares (2021–2025)
The table below shows the annual total assets of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $153.71 Million | -25.51% |
| 2024-12-31 | $206.36 Million | +20.49% |
| 2023-12-31 | $171.26 Million | +69.57% |
| 2022-12-31 | $101.00 Million | +20.23% |
| 2021-12-31 | $84.00 Million | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more